The mid-market private equity (PE) firm Parcom Capital acquired the virology contract research organization (CRO) from Glide Healthcare Partners, which bought a majority stake in the company in 2013.
“We are entering a new growth phase and the acquisition by Parcom Capital will give us the opportunity to expand our service portfolio,” Viroclinics Biosciences CEO, Bob van Gemen told Outsourcing-Pharma.com.
“With Parcom’s Capital platform, our growth rate is accelerated. This means that we are looking into the option of acquiring other companies with specialist knowledge.”
van Gemen said potential new services include: vaccine ingredients production, new test development for viral targets, and big data
“The major benefit [of the acquisition] is that our service offering is expanded for our customers,” added van Gemen.
Specifically, Viroclinic – which has more than 100 employees globally – is looking to portfolio in other target areas, such as Hepatitis, Polio, SARS, Avian/ Bird Flu, and Rabies.
Financial details of the acquisition were not disclosed.